EUVIMEDOdkrijte EUVIMED
CrossrefInformačná karta

Adjunctive intra-arterial thrombolysis with endovascular thrombectomy for acute large-vessel occlusion stroke: a network meta-analysis of randomized trials

Junqi Ma, Ruige Li, Chenfei Lu, Jinping Wang, Yankun Chen, Xiaodu Yu

Frontiers in Medicine · 2026-11-04 · 13

DOI: 10.3389/fmed.2026.1915195 ↗
AbstraktBibliografické údaje

Abstrakt

Background While endovascular thrombectomy (EVT) is standard care for acute ischemic stroke due to large vessel occlusion (AIS-LVO), but nearly half of patients with successful reperfusion do not achieve functional independence. Adjunctive intra-arterial thrombolysis (IAT) aims to address residual distal thrombi and microcirculatory impairment; however, the efficacy and safety of IAT in comparison with other thrombolytics remain uncertain. Methods We conducted a network meta-analysis (NMA) of randomized controlled trials (RCTs) comparing EVT alone vs. EVT combined with IAT using alteplase (ALT), tenecteplase (TNK), or urokinase (UK) in AIS-LVO patients. Primary outcomes were excellent clinical outcome (mRS 0–1) and functional independence (mRS 0–2) at 90 days. Safety outcomes included symptomatic intracranial hemorrhage (sICH) and all-cause mortality. Results Eight RCTs involving 2,564 patients were included. For excellent clinical (mRS 0–1), EVT + IA-ALT ranked highest [surface under the cumulative ranking curve (SUCRA) 96.2%], followed by EVT + IA-TNK (59.8%). Both showed significant benefits over EVT alone [EVT + IA-TNK vs. EVT: RR 1.20, 95% CI 1.05–1.39. EVT + IA-ALT vs. EVT: RR 1.40, 95% CI 1.21–1.63 and EVT + IA-TNK (0.125 mg/kg) vs. EVT: RR 1.54, 95% CI 1.07–2.20. EVT + IA-ALT (0.225 mg/kg) vs. EVT: RR 1.40, 95% CI 1.21–1.63]. For functional independence (mRS 0–2), EVT + IA-ALT also ranked highest, but no combination strategy showed a statistically significant benefit over EVT alone in pairwise comparisons. Regarding safety, point estimates for sICH risk did not differ significantly between combination strategies and EVT alone. However, EVT + IA-TNK demonstrated a statistically significant advantage over EVT + IA-ALT in terms of lower all-cause mortality (RR 1.58, 95% CI 1.01–2.46). Conclusions EVT + IA-ALT and EVT + IA-TNK may improve excellent clinical outcome without a statistically significant increase in sICH; however, clinically important bleeding risk cannot be excluded. In exploratory indirect comparisons, EVT + IA-TNK was associated with lower all-cause mortality than EVT + IA-ALT, although this finding is based on sparse evidence and should be interpreted with caution. Systematic Review Registration PROSPERO CRD420261465567.

Vedomosti, ktoré zodpovedajú vašej práci.

Od bezplatného začiatku cez osobnú rešerš literatúry až po kompletný Research Suite.

Zobraziť tarify →

Sú zahrnuté všetky plné texty vydavateľov?

Nie. Bibliografické záznamy, abstrakty a plné texty sú odlišné typy obsahu. To, či je plný text dostupný, závisí od zdroja, Open Access a vašich existujúcich licencií. Tarif EUVIMED nenahrádza dodatočné práva vydavateľa.

Zobraziť tarify →